XPO1 and hepatocellular carcinoma: In the human HCC cell line SNU-449, blocking MYC activity using the MAX/MAX homodimer stabilizer MS2-00857 mitigated the effects of both XPO1 and PRMT5 inhibition on cell metabolic fitness (Supplementary Fig. 7c) and led to a modest increase in biomass accumulation at high inhibitor concentrations compared to control (Supplementary Fig. 7d).